secwatch.observer — SEC 8-K summary
======================================

Issuer:     IMMUCELL CORP /DE/ (ICCC)
CIK:        0000811641
Form:       8-K
Filed at:   2025-02-25T23:59:59+00:00
Accession:  0001213900-25-017067
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ImmuCell Q4 product sales up 52% to $7.8M; net income $515k vs loss year ago
----------------------------------------------------------------------------

- Product sales for Q4 2024 rose 52% to ~$7.8M; full-year sales up 52% to ~$26.5M.
- Q4 net income of $515k ($0.06 diluted EPS) vs net loss of $1.14M ($0.15) in Q4 2023.
- Gross margin improved to 37% in Q4 2024 from 25% in Q4 2023; EBITDA turned positive at $1.33M.
- No contamination events since April 2024; management believes remediation is effective.
- Pending FDA clearance for Re-Tain®; NADA submitted Jan 2025 seeking expedited review.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/811641/000121390025017067/0001213900-25-017067-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/811641/000121390025017067/ea0232079-8k_immucell.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-017067

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer